FBXO2

Across TCGA pan-cancer cohorts, FBXO2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated FBXO2 data layer compared with 22 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher FBXO2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated FBXO2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

CCRCC, LUAD, and UCEC are the cancer types where FBXO2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	III,IV	0.198	0.887	.024	6	view →
LUAD	DFS	Median	All	0.762	0.490	.005	6	view →
UCEC	OS	Tertile	All	0.845	0.973	.045	4	view →
GBM	OS	Quartile	All	0.339	0.694	.030	2	view →
LSCC	OS	Median	III,IV	0.826	0.418	.015	2	view →
HNSC	OS	Median	All	0.957	1.000	.017	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

FBXO2–CCRCC (DFS)

Open the CCRCC breakdown →